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Abstract
Objective: Despite recommendations to discontinue prophylactic antibiotics after incision closure or <24 hours after surgery, prophylactic
antibiotics are continued after discharge by some clinicians. The objective of this study was to determine the prevalence and factors associated
with postdischarge prophylactic antibiotic use after spinal fusion.
Design: Multicenter retrospective cohort study.
Patients: This study included patients aged ≥18 years undergoing spinal fusion or refusion between July 2011 and June 2015 at 3 sites. Patients
with an infection during the surgical admission were excluded.
Methods: Prophylactic antibiotics were identified at discharge. Factors associated with postdischarge prophylactic antibiotic use were
identified using hierarchical generalized linear models.
Results: In total, 8,652 spinal fusion admissions were included. Antibiotics were prescribed at discharge in 289 admissions (3.3%). The most
commonly prescribed antibiotics were trimethoprim/sulfamethoxazole (22.1%), cephalexin (18.8%), and ciprofloxacin (17.1%). Adjusted for
study site, significant factors associated with prophylactic discharge antibiotics included American Society of Anesthesiologists (ASA) class ≥3
(odds ratio [OR], 1.31; 95% CI, 1.00–1.70), lymphoma (OR, 2.57; 95% CI, 1.11–5.98), solid tumor (OR, 3.63; 95% CI, 1.62–8.14), morbid
obesity (OR, 1.64; 95% CI, 1.09–2.47), paralysis (OR, 2.38; 95% CI, 1.30–4.37), hematoma/seroma (OR, 2.93; 95% CI, 1.17–7.33), thoracic
surgery (OR, 1.39; 95% CI, 1.01–1.93), longer length of stay, and intraoperative antibiotics.
Conclusions: Postdischarge prophylactic antibiotics were uncommon after spinal fusion. Patient and perioperative factors were associated
with continuation of prophylactic antibiotics after hospital discharge.
(Received 27 November 2019; accepted 29 March 2020; electronically published 5 May 2020)

Surgical site infections (SSIs) are among the most common
healthcare-associated infections in the United States.1 The most
recent Centers for Disease Control and Prevention (CDC) guidelines for the prevention of SSI recommend against administration
of prophylactic antibiotics in clean surgeries after the surgical
incision is closed, even in the presence of surgical drains,2
due to lack of data showing the benefit of this practice. Other
organizations recommend discontinuing prophylactic antibiotics
at the completion of surgery.3-5 In practice, compliance with antibiotic discontinuation within 24 hours of surgery varied from
58% to 100% in a study of National Surgical Quality Improvement Program hospitals.6,7
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In a recent systematic review, the pooled incidence of SSI
after spine surgery was 3.1% (range, 0.2%–16.1%). Variation in
SSI rates is associated with the indication for surgery (eg, scoliosis),
instrumentation, duration of surgery, and surgical approach.8
Information in the literature regarding postoperative antibiotic
prophylaxis is limited,9-16 and information on postdischarge
antibiotic prophylaxis17 and its impact on SSI rates after spinal
fusion procedures is sparse. Most studies analyzing the impact
of postoperative or postdischarge antibiotics report no difference in SSI rates between short versus prolonged antibiotic prophylaxis after spine procedures.9-15,17 Overall, high-quality data
are lacking because these studies in general were underpowered
to detect a difference in SSI rates given small sample sizes and
low incidence of SSI.
A concern with the use of postoperative antibiotic prophylaxis
is exposure of patients to unnecessary antibiotics. Unnecessary antibiotics may result in additional costs, adverse drug events, selection of
antibiotic-resistant bacteria,18 and the development of Clostridioides
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difficile infection.19-22 The goals of our study were to determine the
prevalence of postdischarge prophylactic antibiotic use and to identify
patient characteristics, operative factors, and surgeon characteristics
associated with use in a cohort of adults undergoing spinal fusion
at 3 academically affiliated hospital study sites.

David K. Warren et al

Table 1. Categorization of Postdischarge Antibiotics by Class or Activity against
Specific Organisms
Antibiotic Group
Anti–methicillin-resistant
Staphylococcus aureus

Antibiotic Name

No. Dischargeda

Clindamycin

20

Doxycycline

17

Methods

Linezolid

0

Data source

Minocycline

2

We conducted a retrospective cohort study using electronic health
record (EHR) and billing data from 6 hospitals at 3 study sites in
different geographic regions of the country. Site 1 included 1 academic and 1 community hospital; site 2 included 1 academic
hospital; and site 3 comprised 1 academic and 2 community hospitals. Information was collected using queries of the respective
hospital EHR systems and from manual medical record reviews.

Trimethoprim/
sulfamethoxazole

Anti–methicillin-sensitive
S. aureus

Spinal fusion population
We identified spinal fusion operations among adults aged ≥18
years admitted between July 1, 2011 and June 30, 2015. Spinal
fusion or refusion was defined using International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) procedure codes 81.00–81.08 and 81.30–81.39,
respectively. We verified the spinal fusion procedures using
provider Current Procedural Terminology, 4th edition (CPT-4)
coding for spinal fusion (Appendix Table 1 online) for 1 study site
and by reviewing the operating room log for the surgeon description
and anesthesia duration for the remaining 2 sites.
We excluded surgical admissions for patients who would
likely have had antibiotics prescribed at discharge for therapeutic indications based on ICD-9-CM diagnosis codes during the
fusion admission (gunshot wound, motor vehicle accident, SSI/
cellulitis, pneumonia, urinary tract infection, sepsis, upper respiratory tract bacterial infections, serious gastrointestinal infections). We also excluded admissions for which a patient was
discharged on intravenous (IV) antibiotics (Appendix Table 2
online), admissions lacking ICD-9-CM diagnosis codes (due
to lack of comorbidity information), and admissions with a
length of stay of >90 days, and/or admissions during which
the patient died during the spinal fusion surgical admission.

Fluoroquinolones

Other antibiotics

Postdischarge prophylactic antibiotics
Prophylactic antibiotics were defined as oral antibiotics prescribed
at discharge in the absence of an infectious diagnosis during the
surgical admission. If the patient was admitted on oral antibiotic
therapy and the same antibiotic was prescribed at discharge, the
antibiotic was not considered prophylactic. We characterized the
distribution of individual antibiotics and grouped antibiotics based
on activity against specific organisms or by class (Table 1).
Factors associated with prophylactic antibiotic use
Potential factors associated with prophylactic antibiotic use
included patient factors (eg, demographics and comorbidities23),
operative factors, and surgeon characteristics with clinical or biological plausibility for association with antibiotic use and/or risk
for SSI. Comorbidities were defined using ICD-9-CM diagnosis
codes23 and operative factors were defined using ICD-9-CM
diagnosis and procedure codes during the surgical admission
(Appendix Table 3 online). Demographics and other surgical
details were abstracted from the medical records. Morbid obesity

66

Tetracycline

1

Amoxicillin/
clavulanate

20

Cefaclor

0

Cefadroxil

9

Cefdinir

2

Cefixime

0

Cefpodoxime

2

Cefprozil

0

Ceftibuten

0

Cefuroxime

4

Cephalexin

56

Cloxacillin

0

Dicloxacillin

0

Ciprofloxacin

51

Gatifloxacin

0

Gemifloxacin

0

Levofloxacin

17

Moxifloxacin

2

Ofloxacin

0

Amoxicillin

9

Ampicillin

2

Azithromycin

6

Clarithromycin

3

Erythromycin

3

Metronidazole

6

a

There were 298 prophylactic discharge antibiotics among 289 admissions with prophylactic
discharge antibiotics.

was defined as a body mass index ≥40 kg/m2. Surgeon details,
including board certification and specialty, were determined using
the institution and Medicare physician directories.
Complications after spinal fusion
SSIs within 90 days of the spinal operation were identified via standard hospital infection control surveillance using CDC National
Healthcare Safety Network (NHSN) criteria.24 We captured C. difficile infection (ICD-9-CM diagnosis code 008.45) through 90 days
after surgery.
Statistical analyses
Univariate risk factors for prophylactic antibiotic use were evaluated
using the χ2 test, the Fisher’s exact test, logistic regression, or the
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Table 2. Characteristics of 8,652 Spinal Fusion Admissions by Study Site

Variable

Category

Total no. (% of overall population)

Overall

Site 1

Site 2

No. (%)

No. (%)

No. (%)

Site 3

8,652 (100)

4,263 (49.3)

1,589 (18.4)

2,800 (32.4)

4,717 (54.5)

2,302 (54.0)

849 (53.4)

1,566 (55.9)

No. (%)

Patient factors
Sex, female
Age, median y (IQR)
Racea

Payer

58 (49–67)

57 (48–65)

56 (47–66)

60 (51–69)

White

7,271 (84.0)

3,812 (89.4)

1,243 (78.2)

2,216 (79.1)

Black

1,043 (12.1)

354 (8.3)

242 (15.2)

447 (16.0)

Other

209 (2.4)

66 (1.5)

66 (4.2)

77 (2.8)

4,576 (52.9)

2,575 (60.4)

904 (56.9)

1,097 (39.2)

191 (2.2)

184 (4.3)

7 (0.4)

0 (0.0)

Private/VA
Dual Medicare/Medicaid
Medicaid

424 (4.9)

163 (3.8)

174 (11.0)

87 (3.1)

Medicare

3,244 (37.5)

1,277 (30.0)

504 (31.7)

1,463 (52.3)

217 (2.5)

64 (1.5)

0 (0.0)

153 (5.5)

Fall and/or spinal fracture/dislocation

Self-pay/none

676 (7.8)

417 (9.8)

160 (10.1)

99 (3.5)

Cancer

301 (3.5)

181 (4.2)

74 (4.7)

46 (1.6)

Operative factors
LOS, median d (IQR)
Surgical approach

4 (2–6)

4 (2–6)

4 (3–6)

3 (3–5)

Anterior

3,546 (41.0)

1,635 (38.4)

686 (43.2)

1,225 (43.8)

Posterior

4,266 (49.3)

2,318 (54.4)

893 (56.2)

1,055 (37.7)

840 (9.7)

310 (7.3)

10 (0.6)

520 (18.6)

Anterior and posterior
Spinal levels operated upon

1–2 levels

5,958 (68.9)

2,786 (65.4)

1,374 (86.5)

1,798 (64.2)

3–7 levels

2,174 (25.1)

1,108 (26.0)

213 (13.4)

853 (30.5)

≥ 8 levels
Spinal regionb

520 (6.0)

369 (8.7)

2 (0.1)

149 (5.3)

Cervical

4,517 (52.2)

2,408 (56.5)

830 (52.2)

1,279 (45.7)

Lumbar

3,424 (39.6)

1,421 (33.3)

668 (42.0)

1,335 (47.7)

Thoracic

1,324 (15.3)

879 (20.6)

95 (6.0)

350 (12.5)

289 (3.3)

93 (2.2)

81 (5.1)

115 (4.1)

Postdischarge prophylactic antibiotic use
Note. LOS, length of stay; IQR, interquartile range; VA, Veterans’ Affairs.
a
129 (1.5%) admissions were missing race.
b
Categories were not mutually exclusive. 600 (6.9%) patients had >1 spinal region operated upon.

Kruskal-Wallis test, as appropriate. Patient and operative factors
with P < .20 in univariate analysis were included along with study
site in a multivariable logistic regression model with backward selection, with cutoff of P < .10 for inclusion. Multicollinearity was assessed
with tolerance values to ensure independence of explanatory variables. Once the final patient and operative factors were identified,
we developed a hierarchical generalized linear model adding surgeon factors as a second level. We used a random intercept at the
level of the study site and Laplace estimation techniques.25 We performed likelihood ratio tests to assess model fit between the nested
models. Data management was performed using REDCap and SAS
version 9.4 software (SAS Institute, Cary, NC); statistical analyses were
performed using SAS. Post hoc power calculations were performed
using Power Analysis and Sample Size (PASS) version 14 software
(NCSS, Kaysville, UT). This study was approved by the human
research protection offices of the 3 institutions.
Results
The initial study cohort included 9,502 spinal fusion admissions. In
total, 850 admissions were excluded for the following reasons:

infection coded during the fusion admission (n = 599), spinal
fusion was not performed based upon further review (n = 235),
or patient was discharged on IV antibiotics (n = 16). The final
study cohort included 8,652 spinal fusion admissions: 4,263
(49.3%) at study site 1; 1,589 (18.4%) at site 2; and 2,800
(32.4%) at site 3. None of the sites performed routine detection
of intranasal Staphylococcus aureus colonization or decolonization,
and only site 2 recommended preoperative bathing with
chlorhexidine for spinal fusion patients during the study period.
In the final cohort of fusion admissions, the median age of patients
was 58 years (interquartile range, 49–67); 4,717 (54.5%) were female;
676 (7.8%) had trauma (ie, sustained a fracture/dislocation and/or
fall); and 301 (3.5%) had underlying cancer (Table 2).
Prevalence and class of prophylactic antibiotics
Prophylactic antibiotics were prescribed post discharge after
289 spinal fusion admissions (3.3%); after 93 admissions (2.2%)
at site 1, 81 admissions (5.1%) at site 2, and 115 admissions
(4.1%) at site 3 (P < .001). The most commonly prescribed prophylactic antibiotics varied by study site: at site 1, ciprofloxacin
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Table 3. Organisms Identified From 77 Patients With Surgical Site Infection
After Spinal Fusiona
Organism

No. (%)

Staphylococcus aureus
Methicillin-sensitive S. aureus

17 (21.0)

Methicillin-resistant S. aureus

7 (8.6)

Coagulase negative staphylococci

10 (12.3)

Enterococcus spp

2 (2.5)

Streptococcus spp

2 (2.5)

Corynebacterium spp

1 (1.2)

Enterobacteriacae
Escherichia coli

12 (14.8)

Enterobacter cloacae

7 (8.6)

Proteus mirabilis

4 (4.9)

Klebsiella oxytoca

2 (2.5)

Klebsiella pneumoniae

2 (2.5)

Serratia marcescens

2 (2.5)

Citrobacter freundii

1 (1.2)

Morganella morganii

1 (1.2)

Providencia spp
Pseudomonas aeruginosa

1 (1.2)
5 (6.2)

Cutibacterium spp

3 (3.7)

Fusobacterium nucleatum

1 (1.2)

Candida guilliermondii

1 (1.2)

a

Of 77 surgical site infections, 1 was not cultured, 7 were cultured with no growth, and 69 had
a positive culture. The table presents the 81 organisms identified among the 69 infections
with a positive culture; 7 cases had 2 organisms isolated, 1 case had 3 organisms, and 1 case
had 4 organisms isolated.

(27.4%), trimethoprim/sulfamethoxazole (26.3%), and cephalexin
(22.1%) were most commonly prescribed. At site 2, cephalexin
(18.8%), doxycycline (14.1%), and cefadroxil, levofloxacin, and
trimethoprim/sulfamethoxazole were most commonly prescribed
(all at 10.6%). At site 3, trimethoprim/sulfamethoxazole (27.1%),
ciprofloxacin (19.5%), and cephalexin (16.1%) were most commonly prescribed. The distribution of antibiotics prescribed overall
and by site and activity/class are presented in Table 1 and Figure 1.
Antibiotics were prescribed by 16 of 33 spine surgeons (48%) at site
1, 7 of 11 surgeons (64%) at site 2, and 19 of 26 surgeons (73%) at
site 3.
Of the discharges in patients given a prescription for an antiMRSA antibiotic (Table 1), 63 of 106 (59%) received intraoperative
vancomycin or clindamycin prophylaxis. In contrast, of the discharges among patients given a prescription for a first-generation
cephalosporin or amoxicillin/ampicillin/amoxicillin-clavulanate,
89 of 96 (93%) received intraoperative cefazolin prophylaxis.
Incidence of surgical site infection and C. difficile infection
Overall, 77 (0.9%) SSIs were detected by infection preventionists
within 90 days of the spinal fusion procedure: 13 (16.9%) were
classified as superficial incisional; 27 (35.1%) as deep incisional;
and 37 (48.1%) as organ-space SSIs. Cultures were performed
on 76 of the 77 patients, and 69 (90.8%) were positive for 1 or more
organisms (Table 3). Postdischarge prophylactic antibiotic use was
not associated with SSI following spinal fusion: 5 of 289 (1.7%) with

versus 72 of 8,363 (0.9%) without (P = .114). In total, 20 (0.2%)
patients were coded for C. difficile infection within 90 days after
surgery: 1 patient (0.3%) versus 19 patients (0.2%) among admissions with and without postdischarge prophylactic antibiotics,
respectively (P = .494).
Factors associated with prophylactic antibiotic use
In univariate analysis, utilization of prophylactic antibiotics
varied by study site. Compared with patients who did not receive
postdischarge prophylactic antibiotics, those who received postdischarge prophylactic antibiotics were more likely to be female,
to be older, to be of black race, to have Medicare or Medicaid
health insurance, to have had fall and/or spinal fracture/
dislocation, and to have multiple comorbidities (Table 4).
Smokers were less likely to receive postdischarge prophylactic
antibiotics. Operative factors associated with increased likelihood
of postdischarge antibiotics included surgery at a community
hospital, longer surgical admission length of stay, posterior surgical
approach, surgery on the lumbar and thoracic regions, surgery
involving increased number of spinal levels, hematoma/seroma
during the surgical admission, multiple fusion operations during
the surgical admission, and longer surgery duration. Use of vancomycin perioperative prophylaxis, compared with cefazolin or clindamycin only, was associated with increased likelihood of
postdischarge antibiotics. Surgery on the cervical spine was associated with decreased likelihood of receiving postdischarge antibiotics. Surgeon factors associated with use of postdischarge
prophylactic antibiotics were neurosurgical (compared to orthopedic)
specialty and lower spinal fusion surgeon volume (Table 4). On
average, surgeons who performed <50 fusions per year prescribed
postdischarge antibiotics in 7.0% of their procedures, whereas
surgeons who performed 50–99 fusions per year prescribed postdischarge antibiotics in 4.4% of their procedures and surgeons who
performed ≥100 fusions per year prescribed postdischarge antibiotics in 2.9% of their procedures. Although postdischarge prophylactic antibiotics were slightly more likely at a community versus
an academic hospital (Table 4), patients undergoing surgery at
academic hospitals had a significantly higher comorbidity burden
based on the Charlson comorbidity index (P <.001, KruskalWallis test).
We tested whether site-specific surgeon characteristics were
independently associated with the use of postdischarge prophylactic antibiotics using a hierarchical generalized linear model with
random intercepts at the level of the study site (Table 5). The
unconditional model with no patient-level covariates indicated
that there was no significant covariance between patients treated
at the same site (P = .131). The second model included patient
and operative characteristics from the logistic regression model,
and the model fit was significantly better than the empty model
(−2LL = 2,340.15; P < .001). Factors associated with significantly
increased risk of prophylactic antibiotic use after spinal fusion in
multivariable logistic regression analysis were ASA class of 3 or
greater, lymphoma, solid tumor, morbid obesity, paralysis, longer
length of stay, hematoma/seroma, thoracic spinal region, and
choice of intraoperative antibiotic. The third model added surgeon
spinal fusion volume, but model fit was not significantly improved
over model 2 (−2LL = 2,335.53; P = .099).
Discussion
We determined the prevalence, variation, and factors associated
with postdischarge prophylactic antibiotic use after spinal fusion
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Fig. 1. Distribution of postdischarge prophylactic antibiotic group after spinal fusion by study
site. Note. MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillinsensitive S. aureus.

at 3 academic medical center study sites. We found a low prevalence of postdischarge prophylactic antibiotic use, but variation
by study site ranging from 2.2% to 5.1% and by surgeon from
0.5% to 9.8% among surgeons who performed at least 50 spinal
fusions per year. Patient and operative factors associated with
postdischarge antibiotic use included ASA class of 3 or higher, lymphoma, solid tumor, morbid obesity, paralysis, hematoma/seroma,
type of intraoperative antibiotic, surgery on the thoracic spine, and
longer length of stay.
Of the patient-level factors associated with increased use of postdischarge prophylactic antibiotics, morbid obesity,26,27 cancer,28,29
higher ASA score,26,29 and paralysis30 are known to be associated
with increased risk of SSI after spinal fusion. Thoracic surgery
was associated with increased antibiotic use, consistent with
invasiveness of spine surgery31 and correspondingly with increased
risk of SSI.32 The association of these factors suggest that surgeons may be assessing infection risk in patients and selectively
prescribing continuation of prophylaxis for higher risk patients
in an attempt to prevent SSI. Interestingly, there was more consistency in postdischarge use of first-generation cephalosporin
or penicillin in persons who received intraoperative cefazolin
than for use of an anti-MRSA antibiotic in persons who received
intraoperative vancomycin or clindamycin prophylaxis. This
finding suggests that other factors outweighed simple continuation of surgical prophylaxis at hospital discharge.
Although surgeons may be targeting high-risk patients for postdischarge antibiotics, continuing antibiotics after incision closure
is not recommended by the CDC, the European Centre for Disease
Prevention and Control, or the World Health Organization.2-4 The
North American Spine Society does make an exception for complex procedures including trauma, diabetes, obesity, and multilevel
instrumented surgery, but it does not specify a recommended
duration or whether prophylaxis should be discontinued before
discharge.5 There is little evidence that use of prolonged prophylaxis among fusion patients is beneficial.9-17 A single-institution
study found significantly reduced SSI rates in patients undergoing
instrumented spine surgery who were given antibiotic prophylaxis
for 72 hours (2009–2014) compared to a single perioperative dose
(2003–2008), but this finding has not been replicated in other

cohorts and the investigators did not assess utilization of postdischarge antibiotics.16 Inabathula et al33 reported a significant
decrease in infections following hip and knee arthroplasty after
implementing oral antibiotic prophylaxis for 7 days postdischarge
among patients at high risk for infection at a single academic medical center. In this study, however, 60% and 70% of the hip and knee
cohorts, respectively, were considered high risk, calling into question the benefit of stratification. In addition to lack of evidence for
benefit among spinal fusion patients, there is clear potential for
harm with unnecessary use of antibiotics, including selection of
antibiotic-resistant bacteria,18 C. difficile infection,19-22 and acute
kidney injury.20 In our study, the incidence of C. difficile did not
differ by discharge antibiotic use; however, our study was not
adequately powered for this comparison.
Inclusion of surgeon factors in the hierarchical model did not
significantly improve the model fit; however, in this model, surgeons who performed 50–99 spinal fusions per year were 1.34
times more likely to prescribe prophylactic antibiotics at discharge than higher-volume surgeons (ie, ≥100 fusions per year).
Low-volume surgeons (<50 fusions per year) trended toward
increased utilization of postdischarge prophylactic antibiotics,
albeit not significantly (odds ratio, 1.20; 95% confidence interval, 0.80–1.80), likely due to the smaller number of fusions by
low-volume surgeons. Given the variation in discharge antibiotic prescribing at the level of the individual physician, surgeon
education would be important to improve the success of hospital
antibiotic stewardship programs.34
Variation existed by study site with respect to postdischarge
antibiotic use and choice of antibiotic. Use of prophylactic discharge antibiotics was highest at site 2 (5.1%), followed by site
3 (4.1%) and was lowest at site 1 (2.2%). Although site 2 had the
highest proportion of fusion admissions with fall and/or spinal
fracture/dislocation (10.1%), the surgeries were generally less
complex and invasive (ie, fewer multilevel and thoracic procedures and smaller percentage involving both anterior and posterior
approaches), and thus carried a lower risk of infection.32
Ciprofloxacin, trimethoprim/sulfamethoxazole, and cephalexin
were the top 3 antibiotic choices for postdischarge prescriptions
at sites 1 and 3. More than 25% of antibiotic prescriptions at
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Table 4. Univariate Factors Associated with Postdischarge Prophylactic Antibiotic Use After Spinal Fusiona
Postdischarge prophylactic
antibiotic use
Yes No. (%)

No No. (%)

289

8,363

Female sex

170 (58.8)

4,547 (54.4)

.135

Age, median y (IQR)

61 (51–69)

58 (49–66)

<.001

Variable

Category

Total

P Value

Patient factors

Raceb

White

235 (81.3)

7,036 (84.1)

Ref

Black

43 (14.9)

1,000 (12.0)

.135

Other

8 (2.8)

201 (2.4)

.632

119 (41.2)

4,457 (53.3)

Ref

Dual Medicare/Medicaid

3 (1.0)

188 (2.2)

.383

Medicaid

24 (8.3)

400 (4.8)

<.001

Medicare

134 (46.4)

3,110 (37.2)

<.001

9 (3.1)

208 (2.5)

.171

39 (13.5)

637 (7.6)

<.001

9 (3.1)

190 (2.3)

.348

Alcohol abuse

8 (2.8)

122 (1.5)

.072

ASA class ≥3

Payer

Private/VA

Self-pay/none
Fall and/or spinal fracture/dislocation
Previous hospitalization within 30 d
Patient factors- comorbidities

187 (64.7)

4,147 (49.6)

<.001

Cancer, lymphoma

7 (2.4)

49 (0.6)

<.001

Cancer, metastatic

12 (4.2)

190 (2.3)

.037

Cancer, solid tumor

8 (2.8)

40 (0.5)

<.001

Chronic heart failure

9 (3.1)

134 (1.6)

.048

Chronic kidney disease

10 (3.5)

184 (2.2)

.155

Chronic pulmonary disease

28 (9.7)

903 (10.8)

.550

Coagulopathy

13 (4.5)

157 (1.9)

.002

Deficiency anemias

19 (6.6)

370 (4.4)

.083

Depression

33 (11.4)

1,045 (12.5)

.586

Diabetes with or without chronic complications

36 (12.5)

972 (11.6)

.664

6 (2.1)

115 (1.4)

.318

Drug abuse
Fluid and electrolyte disorders

45 (15.6)

741 (8.9)

<.001

Hypertension

115 (39.8)

2,889 (34.5)

.065

Hypothyroidism

27 (9.3)

635 (7.6)

.271

Liver disease

2 (0.7)

61 (0.7)

.942

Morbid obesity

29 (10.0)

499 (6.0)

.005

Other neurological disorders

16 (5.5)

400 (4.8)

.556

Paralysis

14 (4.8)

122 (1.5)

<.001

Peripheral vascular disease

7 (2.4)

146 (1.7)

.391

Psychoses

8 (2.8)

201 (2.4)

.691

Pulmonary circulation disease

3 (1.0)

73 (0.9)

.767

8 (2.8)

282 (3.4)

.575

32 (11.1)

1,412 (16.9)

.009

Rheumatoid arthritis/collagen vascular disease
Smoker
Staphylococcus aureus infection within 365 d

1 (0.3)

33 (0.4)

.897

Valvular disease

11 (3.8)

216 (2.6)

.201

Weight loss

2 (0.7)

77 (0.9)

.688

1

93 (32.2)

4,170 (49.9)

Ref

2

81 (28.0)

1,508 (18.0)

<.001

3

115 (39.8)

2,685 (32.1)

Operative factors
Study site

<.001
(Continued)
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Table 4. (Continued )
Postdischarge prophylactic
antibiotic use
Variable

Category

Yes No. (%)

No No. (%)

P Value

Teaching status of hospital

Community

62 (21.5)

1,462 (17.5)

Ref

Academic

227 (78.5)

6,901 (82.5)

.081

275 (95.2)

7,859 (94.0)

.405

1–2 d

32 (11.1)

2,367 (28.3)

Ref

3–4 d

75 (26.0)

2,863 (34.2)

.002

5–6 d

65 (22.5)

1,651 (19.7)

<.001

≥7 d

117 (40.5)

1,482 (17.7)

<.001

Anterior

70 (24.2)

3,476 (41.6)

Ref

Posterior

185 (64.0)

4,081 (48.8)

<.001

Inpatient procedure
Length of stay

Surgical approach

Spinal levels operated upon

Spinal region

c

Anterior and posterior

34 (11.8)

806 (9.6)

.001

1–2 levels

165 (57.1)

5,793 (69.3)

Ref

3–7 levels

97 (33.6)

2,077 (24.8)

<.001

≥8 levels

27 (9.3)

493 (5.9)

.002

Cervical

101 (34.9)

4,416 (52.8)

<.001

Lumbar

150 (51.9)

3,274 (39.1)

<.001

Thoracic

75 (26.0)

1,249 (14.9)

<.001

Bone morphogenetic protein use

62 (21.5)

1,605 (19.2)

.338

Dural tear

10 (3.5)

217 (2.6)

.366

Hemorrhage

1 (0.3)

18 (0.2)

.641

Hematoma/seroma

6 (2.1)

35 (0.4)

<.001

Multiple spinal fusion operations during admission

11 (3.8)

174 (2.1)

.046

Surgery duration >254 minutes (>75 percentile for cohort)

190 (65.7)

6,310 (75.5)

<.001

Cefazolin or clindamycin only

138 (47.8)

4,608 (55.1)

Ref

Any vancomycin

th

Intraoperative antibiotics

Year

134 (46.4)

3,397 (40.6)

.026

Single antibiotic (other than vancomycin,
cefazolin, or clindamycin) or >1 antibiotic

13 (4.5)

289 (3.5)

.170

No antibiotic documented

4 (1.4)

69 (0.8)

.205
.491

2011

19 (6.6)

535 (6.4)

2012

39 (13.5)

1,336 (16.0)

Ref

2013

68 (23.5)

1,714 (20.5)

.133

2014

114 (39.4)

3,127 (37.4)

.238

2015

49 (17.0)

1,651 (19.7)

.940

259 (89.6)

7,599 (90.9)

.471

Surgeon factors
US medical school graduate
Medical school graduation year

Specialty

Surgical volume (cases per year)

1970–1979

15 (5.2)

402 (4.8)

Ref

1980–1989

86 (29.8)

2,817 (33.7)

.481

1990–1999

64 (22.1)

1,781 (21.3)

.898

≥2000

124 (42.9)

3,363 (40.2)

.966

Neurosurgery

177 (61.2)

4,650 (55.6)

.058

Orthopedics

112 (38.8)

3,713 (44.4)

Ref

<50

33 (11.4)

826 (9.9)

.046

50–99

120 (41.5)

2,483 (29.7)

<.001

≥ 100

136 (47.1)

5,054 (60.4)

Ref

NOTE. ASA class, American Society of Anesthesiologists (ASA) Physical Status Classification System; IQR, interquartile range; Ref, reference group; VA, Veterans’ Affairs.
a
The following factors had an overall n < 15 and were excluded from the table: acquired immune deficiency syndrome, chronic blood loss anemia, and dehiscence/necrosis.
b
129 admissions were missing race.
c
Categories were not mutually exclusive. 600 (6.9%) patients had >1 spinal region operated upon.
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Table 5. Hierarchical Model of Factors Associated With Postdischarge Prophylactic Antibiotic Use after Spinal Fusiona
Model 2, Including Patient and Operative
Factors Final Model

Model 3, including Patient, Operative,
And Surgeon Factors

OR (95% CI)

OR (95% CI)

ASA class ≥ 3

1.31 (1.00–1.70)

1.32 (1.01–1.71)

Cancer, lymphoma

2.57 (1.11–5.98)

2.55 (1.09–5.93)

Cancer, solid tumor

3.63 (1.62–8.14)

3.54 (1.58–7.95)

Morbid obesity

1.64 (1.09–2.47)

1.67 (1.11–2.52)

Paralysis

2.38 (1.30–4.37)

2.39 (1.30–4.39)

Smoker

0.71 (0.49–1.05)

0.72 (0.49–1.05)

1–2 d

1.00

1.00

3–4 d

1.19 (0.76–1.86)

1.16 (0.74–1.82)

5–6 d

1.79 (1.10–2.91)

1.77 (1.09–2.87)

≥7d

Variable

Category

Patient factors

Operative factors
Length of stay

3.32 (2.07–5.32)

3.17 (1.98–5.10)

Hematoma or seroma

2.93 (1.17–7.33)

3.01 (1.20–7.54)

Lumbar spinal region

1.26 (0.96–1.65)

1.27 (0.97–1.67)

Thoracic spinal region

1.39 (1.01–1.93)

1.33 (0.96–1.84)

Intraoperative antibiotics

Cefazolin/clindamycin-only

1.00

1.00

Any vancomycin

1.27 (0.95–1.69)

1.19 (0.89–1.60)

Single antibiotic (other than
vancomycin, cefazolin,
or clindamycin) or >1 antibiotic

1.68 (0.91–3.07)

1.60 (0.87–2.93)

No antibiotic documented

3.31 (1.15–9.54)

3.10 (1.07–8.99)

Surgeon factors
Surgical volume
(cases per year)

< 50

1.20 (0.80–1.80)

50–99

1.34 (1.03–1.76)

≥ 100

1.00

Model fit
−2LLb

2,340.15

2,335.53

P

<0.001

0.099d

c

NOTE. ASA class, American Society of Anesthesiologists (ASA) Physical Status Classification System; CI, confidence interval; LL, log-likelihood; OR, odds ratio.
a
Hierarchical generalized linear model with random intercepts at the level of the hospital site.
b
Empty model −2LL = 2,505.50.
c
P value comparing −2LL of the model with patient and operative factors versus the empty model with only random effects for study site.
d
P value comparing −2LL of model 3 with patient, operative, and surgeon factors versus model 2 with only patient and operative factors.

sites 1 and 3 were for trimethoprim/sulfamethoxazole, suggesting
that surgeons at these sites were concerned about prophylaxis
against methicillin-resistant S. aureus. Site 2 used a broader
mix of postdischarge antibiotics than the other 2 sites, with cephalexin and doxycycline most commonly prescribed. During
the study period, the antibiotic stewardship program at site 2
restricted use of fluoroquinolones during inpatient stays, which
may have carried over to the prescribing pattern of discharge
antibiotics. In contrast, use of doxycycline or levofloxacin was
rare at sites 1 and 3 (cumulative 2.1% and 9.3% by site, respectively). Antibiotic heterogeneity was not explained by the number of surgeons. Site 2 had the most variation in antibiotics, but
only 7 spine surgeons prescribed postdischarge antibiotics. Sites
1 and 3 had less heterogeneity in antibiotic choice, but more surgeons who prescribed postdischarge antibiotics (16 and 19 surgeons, respectively).

Our study has several limitations. We included only 3 study
sites, so our findings might not reflect practices in the community, particularly community hospitals that are not associated
with a teaching hospital. We did not collect information on continuation of prophylactic antibiotics after incision closure or use
of intraoperative vancomycin powder before incision closure.
Misclassification of a therapeutic antibiotic as prophylactic may
have occurred if an infectious diagnosis was not recorded during
the fusion admission and/or if a continued therapeutic antibiotic
was only coded at discharge and not at hospital admission.
Because of low postdischarge antibiotic use in our study cohort,
our study did not have enough power to detect differences in
SSI or C. difficile infection rates by postdischarge antibiotic use
or by individual surgeon. Notably, in our hierarchical model, study
site was not significantly associated with variation in postdischarge
antibiotic use, likely due to the small number of study sites with
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insufficient power to identify clustering. A future study with additional study sites would be of interest. Although the surgeon volume variable did not significantly improve our hierarchical model,
we observed a trend toward more postdischarge antibiotic use by
lower-volume surgeons. Future studies examining surgeon-based
factors for prescribing postdischarge antibiotics would be helpful
given that guidelines recommend against prolonged use of postoperative prophylactic antibiotics.
In summary, postdischarge prophylactic antibiotic use was
uncommon after spinal fusion but varied by study site. Patient
characteristics associated with risk of SSI were associated with
use of postdischarge prophylactic antibiotics. Stewardship efforts
to discourage continuation of antibiotics after hospital discharge
are needed to avoid further increases in antimicrobial resistance
and adverse events.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/ice.2020.117
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